Literature DB >> 21756857

FGL2/fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice.

Nazia Selzner1, Hao Liu, Markus U Boehnert, Oyedele A Adeyi, Itay Shalev, Agata M Bartczak, Max Xue-Zhong, Justin Manuel, Ori D Rotstein, Ian D McGilvray, David R Grant, Melville J Phillips, Gary A Levy, Markus Selzner.   

Abstract

BACKGROUND & AIMS: Sinusoidal endothelial cell (SEC) and hepatocyte death are early, TNF-α mediated events in ischemia and reperfusion of the liver (I/Rp). We previously reported that TNF-α induced liver injury is dependent on Fibrinogen like protein 2 (FGL2/Fibroleukin) and showed that FGL2 binding to its receptor, FcγRIIB, results in lymphocyte apoptosis. In this study we examine whether I/Rp is induced by specific binding of FGL2 to FcγRIIB expressed on SEC.
METHODS: Hepatic ischemia and reperfusion was induced in wild type (WT) mice and in mice with deletion or inhibition of FGL2 and FcRIIB. Liver injury was determined by AST release, necrosis and animal death. Apoptosis was evaluated with caspase 3 and TUNEL staining.
RESULTS: FGL2 deletion or inhibition resulted in decreased liver injury as determined by a marked reduction in both levels of AST and ALT and hepatocyte necrosis. Caspase 3 staining of SEC (12% vs. 75%) and hepatocytes (12% vs. 45%) as well as TUNEL staining of SEC (13% vs. 60%, p=0.02) and hepatocytes (18% vs. 70%, p=0.03), markers of apoptosis, were lower in Fgl2(-/-) compared to WT mice. In vitro incubation of SEC with FGL2 induced apoptosis of SEC from WT mice, but not FcγRIIB(-/-) mice. Deletion of FcγRIIB fully protected mice against SEC and hepatocyte death in vivo. Survival of mice deficient in either Fgl2(-/-) (80%) or FcγRIIB(-/-) (100%) was markedly increased compared to WT mice (10%) which were subjected to 75min of total hepatic ischemia (p=0.001).
CONCLUSIONS: FGL2 binding to the FcγRIIB receptor expressed on SEC is a critical event in the initiation of the hepatic reperfusion injury cascade through induction of SEC and hepatocyte death.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756857     DOI: 10.1016/j.jhep.2011.05.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

1.  Hydrogen-Rich Saline Ameliorates Hepatic Ischemia-Reperfusion Injury Through Regulation of Endoplasmic Reticulum Stress and Apoptosis.

Authors:  Zhiyuan Lu; Yanzhu Lin; Bo Peng; Zhen Bao; Kexin Niu; Jin Gong
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

Review 2.  Fibrinogen-Related Proteins in Tissue Repair: How a Unique Domain with a Common Structure Controls Diverse Aspects of Wound Healing.

Authors:  Lorena Zuliani-Alvarez; Kim S Midwood
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-05-01       Impact factor: 4.730

Review 3.  The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Authors:  Jiemiao Hu; Jun Yan; Ganesh Rao; Khatri Latha; Willem W Overwijk; Amy B Heimberger; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-09-26       Impact factor: 5.311

4.  Physiological functions and clinical implications of fibrinogen-like 2: A review.

Authors:  Genyan Yang; W Craig Hooper
Journal:  World J Clin Infect Dis       Date:  2013-08-25

Review 5.  Targeting the Hepatic Microenvironment to Improve Ischemia/Reperfusion Injury: New Insights into the Immune and Metabolic Compartments.

Authors:  Fengqiang Gao; Xun Qiu; Kai Wang; Chuxiao Shao; Wenjian Jin; Zhen Zhang; Xiao Xu
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

6.  Von Willebrand factor protects against acute CCl4-induced hepatotoxicity through phospho-p38 MAPK signaling pathway inhibition.

Authors:  Hai-Jian Sun; Jian Chen; Hao Zhang; Bing Ni; Jennifer C van Velkinburgh; Yao Liu; Yu-Zhang Wu; Xia Yang
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

7.  Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis.

Authors:  Koichi Yanaba; Yoshihide Asano; Shinji Noda; Kaname Akamata; Naohiko Aozasa; Takashi Taniguchi; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Hayakazu Sumida; Yoshihiro Kuwano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2012-09-16       Impact factor: 2.980

8.  New drug delivery system for liver sinusoidal endothelial cells for ischemia-reperfusion injury.

Authors:  Naoki Sano; Takafumi Tamura; Naoyuki Toriyabe; Takeshi Nowatari; Ken Nakayama; Tomohito Tanoi; Soichiro Murata; Yu Sakurai; Mamoru Hyodo; Kiyoshi Fukunaga; Hideyoshi Harashima; Nobuhiro Ohkohchi
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

9.  Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis.

Authors:  Xue-Zhong Ma; Agata Bartczak; Jianhua Zhang; Wei He; Itay Shalev; David Smil; Limin Chen; Jim Phillips; Jordan J Feld; Nazia Selzner; Gary Levy; Ian McGilvray
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

10.  Novel antibody against a glutamic acid-rich human fibrinogen-like protein 2-derived peptide near Ser91 inhibits hfgl2 prothrombinase activity.

Authors:  Wen-Zhu Li; Jue Wang; Rui Long; Guan-Hua Su; Dinesh-Kumar Bukhory; Jing Dai; Nan Jin; Shi-Yuan Huang; Peng Jia; Ting Li; Chen Fan; Kun Liu; Zhaohui Wang
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.